Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module

Polypharmacy Clinical Trial

— OLD-NH-QC-DeMo  

Official title:

Opportunities and Limits to Deprescribing in Nursing Homes:Quality Circle Deprescribing Module

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03688542
• Other study ID #: OLD-NH-QC-DeMo-2017
• Status: Completed
• Phase: N/A
• Start date: September 25, 2017
• Est. completion date: July 1, 2020

Study information

• Verified date: March 2021
• Source: University of Geneva, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Older people residing in nursing homes (NH) are frequently polymedicated and often prescribed potentially inappropriate medications. Deprescribing has been proposed as a way to reduce the number of drugs they receive and their exposure to harmful treatments.

The objectives of this study are 1) To evaluate the effect of a deprescribing-specific interdisciplinary quality circle module on the use of potentially inappropriate medication in nursing-home residents. 2) To determine the effective strategies to reach and implement deprescribing consensus resulting of said quality circle module.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 56
• Est. completion date: July 1, 2020
• Est. primary completion date: July 1, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

Nursing homes taking part in the study must have

• a geriatric of psycho-geriatric mission;

• been part of their cantonal pharmaceutical assistance program for at least a year.

Exclusion Criteria:

• None

Related Conditions & MeSH terms

• Inappropriate Prescribing
• Polypharmacy

Intervention

Other:
• Quality Circle Deprescribing Module
The Quality Circle Deprescribing Module consist of a discussion bringing together nurses, physicians and responsible pharmacist to create a local deprescribing consensus for frequently used drug classes, as well as implementation strategies for the consensus..

Locations

Country	Name	City	State
Switzerland	Centre de Pharamacie Communautaire	Lausanne	Vaud

Sponsors (1)

Lead Sponsor	Collaborator
Anne Niquille

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of Potentially Inappropriate Galenic Units	The primary outcome is the percentage, at follow-up, of potentially inappropriate galenic units at follow-up, relative to the total number of galenic units used in the nursing home.	12 months
Primary	Number of Potentially Inappropriate Defined Daily Doses (DDDs) Per Average Resident and Per Day	Sum of Defined Daily Doses identified as potentially inappropriate (PIM, see protocol for assessement method), divided by the total number of days spent in the NH	12 months
Secondary	Number of Potentially Inappropriate DDD to Avoid	Sum of Defined Daily Doses identified as "to avoid" (see protocol for assessement method), divided by the total number of days spent in the NH.	12 months
Secondary	Number of Potentially Inappropriate DDD to Reevaluate	Sum of Defined Daily Doses identified as "to reevaluate" (see protocol for assessement method), divided by the total number of days spent in the NH.	12 months
Secondary	Number of Hospital Days	The number of days spent in the hospital by average resident	12 months
Secondary	Mortality Rate	Number of residents of the nursing home having died during the considered year, divided by the total number of residents having stayed in the nursing home.	12 months
Secondary	Number of Falls Per Average Resident and Per Year	Number of falls per average resident and per year	12 months
Secondary	Percentage of Residents With at Least One Day of Physical Restraints Use	Number of residents of the nursing home with at least one day of physical restraints use during the considered year, divided by the total number of residents having stayed in the nursing home.	12 months

External Links

•   Website of funding body